BCTC

BCTC is a potent and selective small molecule antagonist of the **Transient Receptor Potential Vanilloid 1 (TRPV1)** channel. It was utilized by researchers at the **Medical University of Vienna** in a randomized, placebo-controlled crossover trial (NCT05275751) to investigate the mechanisms of human heat pain perception. By blocking TRPV1, BCTC was shown to significantly reduce pain induced by noxious heat, confirming the channel's primary role in human thermal nociception. The compound is primarily used as a pharmacological research tool to study pain pathways and the functional roles of TRP channels in experimental settings rather than as a commercially marketed therapeutic.

Other names

N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamideTRPV1 inhibitorTRPV-1 inhibitorTRPV 1 inhibitor4-(3-Chloro-2-pyridinyl)-N-[4-(1,1-dimethylethyl)phenyl]-1-piperazinecarboxamide